UnknownNot Applicable

ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma

China100 participantsStarted 2021-06-01

Plain-language summary

To analyze the relationship between the dynamic changes of circulating tumor DNA (ctDNA) and tumor relapse of esophageal squamous cell carcinoma treated by concurrent chemoradiotherapy.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. 18-75 years old.
✓. ECOG 0-1.
✓. Esophageal squamous cell carcinoma confirmed by pathology.
✓. No radiotherapy, chemotherapy, or other treatments prior to enrollment.
✓. Locally advanced esophageal squamous cell carcinoma (II-IVa, IVB with supraclavicular lymph node metastasis).
✓. No severe abnormal hematopoietic, cardiac, pulmonary, renal, hepatic function, or immunodeficiency.
✓. Informed consent signed.

Exclusion criteria

✕. Less than 50.4Gy/28fx of radiotherapy dose.
✕. Without Concurrent chemotherapy.
✕. Pregnant or breastfeeding women or fertile patients who refused to use contraceptives.

What they're measuring

Relationship between ctDNA status after chemoradiotherapy and relapse.

Timeframe: ctDNA will be tested within 1 year after chemoradiotherapy

Trial details

NCT IDNCT05426850

SponsorFudan University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-12-31

View on ClinicalTrials.gov More Esophageal Squamous Cell Carcinoma trials